Categories: Financial Results

HealthCare Global Enterprises Ltd. reports Q3-FY18 results

Revenue for Q3 FY18 of INR 2,063 Million, a growth of 17% (y-o-y) and for 9M FY18 of INR 6,084 Million, a growth of 17.5% (y-o-y)

EBITDA for Q3 FY18 at INR 319 Million, a growth of 15.3% (yo-y) and for 9M FY18 of INR 968 Million, a growth of 19.4% (y-o-y)

Bengaluru, February 09, 2018: HealthCare Global Enterprises Limited (“HCG”) today announced its financial results for the quarter (“Q3 FY18”) and nine months (“9M FY18”) ended December 31, 2017.

Highlights for quarter ended December 31st, 2017

Consolidated Income from Operations (“Revenue”) was INR 2,063 mn as compared to INR 1,762 mn in the corresponding quarter of the previous year, reflecting a year-on-year increase of 17%.
Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was INR 319 mn as compared to INR 277 mn in the corresponding quarter of the previous year, reflecting a year-on-year increase of 3%.
Operating EBITDA without loss from new centers was INR 309 mn as compared to INR 274 mn in the corresponding quarter of the previous
Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”) was INR 261 mn as compared to INR 260 mn in the corresponding quarter of the previous year, reflecting a year-on-year increase of 3%.
Consolidated Profit after Taxes and Minority Interest (“PAT”)(4) was INR 32 million as compared to INR 54 mn in the corresponding quarter of the previous

INR million except earnings per share

Period Ended Dec 31	Q3-FY18	Q3-FY17	Growth (y-o-y)	YTD-FY18	YTD-FY17	Growth (y-o-y)
Income from Operations	2,063	1,762	17.1%	6,084	5,177	17.5%
Other Income	59	17		102	61
EBITDA⁽¹⁾	319	277	15.3%	968	811	19.4%
EBITDA Margin (%)	15.1%	15.6%		15.7%	15.5%
Operating EBITDA⁽²⁾	261	260	0.3%	866	750	15.5%
EBITDA Margin (%)	12.6%	14.8%		14.2%	14.5%
PBT(3)	35	77	-54.4%	250	232	8.1%
PBT Margin (%)	1.7%	4.4%		4.1%	4.5%
PAT(4)	32	54	-40.4%	179	153	17.4%
PAT Margin (%)	1.5%	3.0%		2.9%	2.9%
Earnings Per Share	0.37	0.62	-40.3%	2.09	1.79	16.8%

Profit before depreciation and amortization, finance costs, exceptional items and taxes

Profit before other income, depreciation and amortization, finance costs, exceptional items and taxes
Profit / (Loss) before tax
Profit / (Loss) for the period after taxes and minority interests

Business Updates for Q3 FY18

Growing strategic focus and scale across
- Nashik expansion and launch of Nagpur and Borivali led to the region contributing 9% of HCG Centers income in Q3 FY18 as compared to 4% in the corresponding quarter of the previous year; this is to further strengthen with upcoming launch of South Mumbai in Q1-FY19
- Borivali center operationalized with commencement of comprehensive radiation, surgical and medical oncology services, all under one roof, in a large and high-realization market
Focus on continued leadership in East India region with strong performance at Cuttack and Ranchi; presence in the region to be augmented further with planned launch of Kolkata center in Q1-FY19
Milann announced plan for new center in Whitefield area towards continuing market leadership in Bengaluru, which remains one of the most attractive markets for fertility

Commenting on the results, Dr. B.S. Ajaikumar, Chairman and CEO, HealthCare Global Enterprises Ltd. said, “We are pleased to report Q3 FY18 results with consistent performance in a changing healthcare landscape. We welcome the announcement from the government which will potentially make high quality healthcare accessible to 500mn people. HCG given our strong presence in Tier 2 and Tier 3 cities across India through our oncology care network is very well positioned in this new landscape. Also, we are very excited about the prospects of the newest addition to the HCG Family – created from the business combination of our Triesta unit with Strand Life Sciences – to create India’s leading speciality diagnostics company. This will redefine precision medicine with end to end expertise spanning bioinformatics, genomics and research. We feel our focused approach in cancer care and fertility treatment, positions us well for the future.”

Earnings Call

The company will conduct a one hour conference call at 5:00 PM IST on Thursday February 8, 2018 where the management will discuss insights about the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91 22 3938 1009 / +91 7045671221. Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau